ly3532226
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 10, 2021 (NCT04923269)
Timeline
Indications
Mechanism of action
GIPR agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068487 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07215559 | Phase 2 | Oct 16, 2025 | Eli Lilly |
| NCT06557356 | Phase 1 | Aug 16, 2024 | Eli Lilly |
| NCT05887999 | Phase 1 | Jun 12, 2023 | Eli Lilly |
| NCT05407961 | Phase 1 | Jun 7, 2022 | Eli Lilly |
| NCT04923269 | Phase 1 | Jun 10, 2021 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 2 | 2021 |
1 organizations
Page 1 / 1